News & Updates

Treatment with the oral highly selective JAK1 inhibitor ivarmacitinib appears to help reduce disease activity in patients with moderate-to-severe atopic dermatitis (AD), with up to 42 percent of them having complete or near-complete clearance of involved skin areas, according to the results of the pivotal phase III QUARTZ3 trial presented at AAD 2023.

A free online telepharmacy service, developed in the Philippines during the COVID-19 pandemic, may be used to provide and simplify medication information as part of primary care, reports a study.

Anticoagulation therapy with apixaban yields lower rates of ischaemic stroke and intracranial and extracranial major bleeding compared with other oral anticoagulants (OACs) in patients with atrial fibrillation (AF), with the magnitude of benefit for major bleeding even greater for those who have dementia, according to a study.

A tumour immune barrier (TIB) structure formed by the interaction of SPP1+ macrophages and cancer-associated fibroblasts (CAFs) appears to influence the efficacy of immunotherapy in patients with hepatocellular carcinoma (HCC), reveals a study.

Treatment with secukinumab leads to sustained clinical response among patients with psoriasis, with clinical response being associated with rapid and persistent normalization of keratin 16 (K16) and inflammatory gene expression for most patients, according to data from the ObePso-S study.

The effects of systemic antihypertensive medications on glaucoma and intraocular pressure (IOP) appear to vary widely, according to the results of a systematic review and meta-analysis.